A Unilever proprietary technology has been shown to inhibit biofilm growth and development, and is also found to possess antimicrobial activity, effective both as a broad-spectrum antibacterial and as an antifungal agent. This is unusual and requires both specific and holistic understanding of the agent’s mode of action at a molecular level. In the studies proposed here (performed using the technique of neutron reflectivity), we aim to determine the effect of this potential new drug on model fungal, bacterial and mammalian cell membranes. We hope then to elucidate the key common factors which render the technology effective in controlling biofilm formation as well as exploring the its impact on different infective organisms.